Abstract

BackgroundReactivation of hepatitis in hepatitis B virus (HBV) carrier receiving cytotoxic chemotherapy or immunosuppressive therapy often occur (20-50%), so prophylactic treatment by antiviral agent is recommended with chemotherapy or immunosuppressive...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy
Robert P Perrillo ... Yngve T Falck-Ytter
Gastroenterology | VOL. 148
Robert P Perrillo, et. al.Robert P Perrillo ... Yngve T Falck-Ytter
31 Oct 2014
Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers
Oren Shibolet ... Rifaat Safadi
Blood | VOL. 100
Oren Shibolet, et. al.Oren Shibolet ... Rifaat Safadi
15 Jul 2002
Hepatitis B e Antibody Positive before Rituximab Combination Chemotherapy Is Associated with a Lower Risk of Hepatitis B Virus (HBV) Reactivation in HBV Carriers with Diffuse Large B-Cell Lymphoma
Qingqing Cai ... Zhiming Li
Blood | VOL. 124
Qingqing Cai, et. al.Qingqing Cai ... Zhiming Li
06 Dec 2014
Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy
Winnie Yeo ... Philip J Johnson
Hepatology | VOL. 43
Winnie Yeo, et. al.Winnie Yeo ... Philip J Johnson
01 Jan 2006
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
Expert consensus recommendations for the diagnosis and treatment of chronic non-bacterial osteitis (CNO) in adults
Elizabeth M Winter ... Anne T Leerling
Annals of the Rheumatic Diseases | VOL. -
Elizabeth M Winter, et. al.Elizabeth M Winter ... Anne T Leerling
28 Nov 2024
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial
Jinjing Liu ... Xiaofeng Zeng
Annals of the Rheumatic Diseases | VOL. -
Jinjing Liu, et. al.Jinjing Liu ... Xiaofeng Zeng
27 Nov 2024
CD-19 CAR-T cells for polyrefractory rheumatoid arthritis
Merav Lidar ... Abraham Avigdor
Annals of the Rheumatic Diseases | VOL. -
Merav Lidar, et. al.Merav Lidar ... Abraham Avigdor
27 Nov 2024
Correction: Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment
-
Annals of the Rheumatic Diseases | VOL. -
--
27 Nov 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.